1. Home
  2. MDWD vs AOMR Comparison

MDWD vs AOMR Comparison

Compare MDWD & AOMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • AOMR
  • Stock Information
  • Founded
  • MDWD 2000
  • AOMR 2018
  • Country
  • MDWD Israel
  • AOMR United States
  • Employees
  • MDWD N/A
  • AOMR N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • AOMR Real Estate Investment Trusts
  • Sector
  • MDWD Health Care
  • AOMR Real Estate
  • Exchange
  • MDWD Nasdaq
  • AOMR Nasdaq
  • Market Cap
  • MDWD 208.2M
  • AOMR 238.8M
  • IPO Year
  • MDWD 2014
  • AOMR 2021
  • Fundamental
  • Price
  • MDWD $17.14
  • AOMR $9.83
  • Analyst Decision
  • MDWD Strong Buy
  • AOMR Strong Buy
  • Analyst Count
  • MDWD 2
  • AOMR 6
  • Target Price
  • MDWD $35.00
  • AOMR $11.25
  • AVG Volume (30 Days)
  • MDWD 154.9K
  • AOMR 220.4K
  • Earning Date
  • MDWD 08-14-2025
  • AOMR 11-05-2025
  • Dividend Yield
  • MDWD N/A
  • AOMR 13.04%
  • EPS Growth
  • MDWD N/A
  • AOMR N/A
  • EPS
  • MDWD N/A
  • AOMR 1.56
  • Revenue
  • MDWD $19,858,000.00
  • AOMR $57,661,000.00
  • Revenue This Year
  • MDWD $20.37
  • AOMR N/A
  • Revenue Next Year
  • MDWD $25.91
  • AOMR $13.75
  • P/E Ratio
  • MDWD N/A
  • AOMR $6.28
  • Revenue Growth
  • MDWD N/A
  • AOMR N/A
  • 52 Week Low
  • MDWD $14.14
  • AOMR $7.36
  • 52 Week High
  • MDWD $22.51
  • AOMR $10.88
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 45.84
  • AOMR 53.45
  • Support Level
  • MDWD $16.08
  • AOMR $9.61
  • Resistance Level
  • MDWD $20.30
  • AOMR $10.14
  • Average True Range (ATR)
  • MDWD 0.93
  • AOMR 0.20
  • MACD
  • MDWD 0.20
  • AOMR -0.01
  • Stochastic Oscillator
  • MDWD 25.12
  • AOMR 45.61

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About AOMR Angel Oak Mortgage REIT Inc.

Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.

Share on Social Networks: